F. Payumo

Tissue-engineered skeletal muscle organoids for reversible gene therapy.

H. Vandenburgh, J. Shansky, A. Chang, 1996, Human gene therapy.

First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors.

T. Owonikoko, S. Ramalingam, P. Komarnitsky, 2014 .

Abstract A100: A phase 1, first in human, study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors

M. Cotreau, A. Tolcher, G. Weiss, 2009 .

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

J. Ahn, M. Ahn, Keunchil Park, 2018, Clinical pharmacology in drug development.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma

Keunchil Park, T. Mok, E. Tan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tissue Engineering Skeletal Muscle for Orthopaedic Applications

Lee P. Smith, H. Vandenburgh, H. Keeping, 2002, Clinical orthopaedics and related research.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

C. Hofmeister, M. Cotreau, A. Tolcher, 2014, British Journal of Cancer.

Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

M. Cotreau, T. Mok, E. Tan, 2011, Journal of Clinical Oncology.

Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

M. Cotreau, M. Ahn, E. Tan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

M. Cotreau, A. Tolcher, G. Weiss, 2010 .

An in vivo analysis of bone repair products made by three-dimensional fabrication techniques

John R. Parsons, Jennifer Patterson, T. Dutta Roy, 2001 .